厄洛替尼治疗晚期非小细胞肺癌：临床医生的最新进展。
Erlotinib in the treatment of advanced non-small cell lung cancer: an update for clinicians.
机构信息
Shanghai Pulmonary Hospital, Cancer Institute, School of Medicine, Tongji University, Shanghai, PR China.
出版信息
Ther Adv Med Oncol. 2012 Jan;4(1):19-29. doi: 10.1177/1758834011427927.
Abstract
Inhibition of epidermal growth factor receptor (EGFR) has become an important target in the treatment of advanced non-small cell lung cancer (NSCLC). Erlotinib and gefitinib, two small molecular agents that target the tyrosine kinase domain of the EGFR, were approved in many countries for the treatment of locally advanced or metastatic NSCLC as a second- or third-line regimen. Since then, randomized trials have evaluated the role of these two targeted agents alone or combined with chemotherapy in maintenance and first-line settings. This review summarizes the results of recent clinical trials with these tyrosine kinase inhibitors, with a focus on erlotinib, as first-line treatment towards a form of personalized medicine aimed at improving clinical outcome in advanced NSCLC.
摘要
表皮生长因子受体（EGFR）的抑制已成为治疗晚期非小细胞肺癌（NSCLC）的重要靶点。厄洛替尼和吉非替尼是两种针对 EGFR 酪氨酸激酶结构域的小分子药物，已在许多国家被批准用于治疗局部晚期或转移性 NSCLC 的二线或三线治疗。此后，随机试验评估了这些两种靶向药物单独或联合化疗在维持和一线治疗中的作用。本综述总结了这些酪氨酸激酶抑制剂的最新临床试验结果，重点介绍了厄洛替尼作为一线治疗方案，旨在改善晚期 NSCLC 的临床结局，这是一种个性化医疗的形式。
相似文献
1
Erlotinib in the treatment of advanced non-small cell lung cancer: an update for clinicians.厄洛替尼治疗晚期非小细胞肺癌：临床医生的最新进展。
Ther Adv Med Oncol. 2012 Jan;4(1):19-29. doi: 10.1177/1758834011427927.
2
Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.表皮生长因子受体突变（EGFR）检测对晚期非小细胞肺癌患者使用表皮生长因子受体靶向酪氨酸激酶抑制剂（TKI）药物疗效的预测：一项循证分析
Ont Health Technol Assess Ser. 2010;10(24):1-48. Epub 2010 Dec 1.
3
First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.晚期表皮生长因子受体（EGFR）突变阳性非鳞状非小细胞肺癌的一线治疗
Cochrane Database Syst Rev. 2016 May 25(5):CD010383. doi: 10.1002/14651858.CD010383.pub2.
4
Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.厄洛替尼和吉非替尼用于治疗先前化疗后进展的非小细胞肺癌（英国国家卫生与临床优化研究所技术评估162和175回顾）：一项系统评价与经济学评估
Health Technol Assess. 2015 Jun;19(47):1-134. doi: 10.3310/hta19470.
5
BEVERLY: Rationale and Design of a Randomized Open-Label Phase III Trial Comparing Bevacizumab Plus Erlotinib Versus Erlotinib Alone as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous Non-Small-Cell Lung Cancer.贝弗利：一项随机开放标签III期试验的原理与设计，该试验比较了贝伐单抗联合厄洛替尼与单纯厄洛替尼作为表皮生长因子受体（EGFR）突变的晚期非鳞状非小细胞肺癌患者一线治疗方案的疗效。
Clin Lung Cancer. 2016 Sep;17(5):461-465. doi: 10.1016/j.cllc.2016.04.001. Epub 2016 Apr 22.
6
Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials.吉非替尼和厄洛替尼治疗转移性非小细胞肺癌：随机临床试验毒性和疗效的荟萃分析
Oncologist. 2015 Apr;20(4):400-10. doi: 10.1634/theoncologist.2014-0154. Epub 2015 Mar 20.
7
Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer.表皮生长因子受体抑制在局部晚期非小细胞肺癌综合治疗中的应用
Semin Oncol. 2005 Apr;32(2 Suppl 3):S35-41. doi: 10.1053/j.seminoncol.2005.03.008.
8
9
Erlotinib in non-small cell lung cancer treatment: current status and future development.厄洛替尼在非小细胞肺癌治疗中的现状与未来发展
Oncologist. 2007 Jul;12(7):840-9. doi: 10.1634/theoncologist.12-7-840.
10
Role of erlotinib in first-line and maintenance treatment of advanced non-small-cell lung cancer.厄洛替尼在晚期非小细胞肺癌一线和维持治疗中的作用。
Cancer Manag Res. 2010 Jun 1;2:143-56. doi: 10.2147/cmar.s5398.
引用本文的文献
1
In silico exploration of anticancer plant phytochemicals for EGFR-targeted lung cancer therapy.用于EGFR靶向肺癌治疗的抗癌植物植物化学物质的计算机模拟探索。
Sci Rep. 2025 Jul 30;15(1):27809. doi: 10.1038/s41598-025-10412-4.
2
The impact of 9-azaglycophymine and phenylguanidine derivatives on the proliferation of various breast cancer cell lines in vitro and in vivo.9-氮杂鸟嘌呤和苯胍衍生物对各种乳腺癌细胞系在体外和体内增殖的影响。
Sci Rep. 2024 Nov 15;14(1):28126. doi: 10.1038/s41598-024-71624-8.
3
Overcoming Cancer Resistance: Strategies and Modalities for Effective Treatment.克服癌症耐药性：有效治疗的策略与方式
Biomedicines. 2024 Aug 8;12(8):1801. doi: 10.3390/biomedicines12081801.
4
Alternative and efficient one-pot three-component synthesis of substituted 2-aryl-4-styrylquinazolines/4-styrylquinazolines from synthetically available 1-(2-aminophenyl)-3-arylprop-2-en-1-ones: characterization and evaluation of their antiproliferative activities.由合成可得的1-(2-氨基苯基)-3-芳基丙-2-烯-1-酮进行替代且高效的一锅三组分合成取代的2-芳基-4-苯乙烯基喹唑啉/4-苯乙烯基喹唑啉：其抗增殖活性的表征与评价
RSC Adv. 2024 Jul 2;14(29):20951-20965. doi: 10.1039/d4ra03702b. eCollection 2024 Jun 27.
5
Multidrug-Resistant Profiles in Non-Small Cell Lung Carcinoma Patient-Derived Cells: Implications for Personalized Approaches with Tyrosine Kinase Inhibitors.非小细胞肺癌患者来源细胞中的多药耐药谱：对酪氨酸激酶抑制剂个性化治疗方法的启示
Cancers (Basel). 2024 May 23;16(11):1984. doi: 10.3390/cancers16111984.
6
Multifaceted role of erlotinib in various cancer: nanotechnology intervention, patent landscape, and advancements in clinical trials.厄洛替尼在多种癌症中的多方面作用：纳米技术干预、专利全景及临床试验进展。
Med Oncol. 2024 Jun 12;41(7):173. doi: 10.1007/s12032-024-02414-5.
7
Investigating the Efficacy of EGFR-TKIs and Anti-VEGFR Combination in Advanced Non-Small Cell Lung Cancer: A Meta-Analysis.表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKIs）与抗血管内皮生长因子受体（VEGFR）联合治疗晚期非小细胞肺癌的疗效研究：一项荟萃分析
Cancers (Basel). 2024 Mar 18;16(6):1188. doi: 10.3390/cancers16061188.
8
Primary cilia: a novel research approach to overcome anticancer drug resistance.原发性纤毛：克服抗癌药物耐药性的一种新研究方法。
Front Mol Biosci. 2023 Oct 2;10:1270639. doi: 10.3389/fmolb.2023.1270639. eCollection 2023.
9
Comparing Efficacy of Erlotinib and Bevacizumab Combination with Erlotinib Monotherapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-Analysis.厄洛替尼与贝伐单抗联合用药与厄洛替尼单药治疗晚期非小细胞肺癌（NSCLC）患者的疗效比较：一项系统评价和荟萃分析
Diseases. 2023 Oct 23;11(4):146. doi: 10.3390/diseases11040146.
10
Pyrrolo[2,3-D]Pyrimidines as EGFR and VEGFR Kinase Inhibitors: A Comprehensive SAR Review.吡咯并[2,3-d]嘧啶作为 EGFR 和 VEGFR 激酶抑制剂：全面的 SAR 综述。
Curr Med Chem. 2024;31(36):5918-5936. doi: 10.2174/0929867331666230815115111.
本文引用的文献
1
Final overall survival results from a phase III, randomized, placebo-controlled, parallel-group study of gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804).III 期、随机、安慰剂对照、平行组研究的最终总生存结果，比较吉非替尼与安慰剂作为局部晚期或转移性非小细胞肺癌（INFORM；C-TONG 0804）患者的维持治疗。
J Thorac Oncol. 2015 Apr;10(4):655-64. doi: 10.1097/JTO.0000000000000445.
2
ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer.ATLAS：一项随机、双盲、安慰剂对照的 IIIB 期临床试验，比较贝伐珠单抗联合或不联合厄洛替尼治疗与贝伐珠单抗单药一线治疗晚期非小细胞肺癌的疗效，化疗后完成。
J Clin Oncol. 2013 Nov 1;31(31):3926-34. doi: 10.1200/JCO.2012.47.3983. Epub 2013 Oct 7.
3
A randomized, phase II, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancer.一项随机、二期、基于生物标志物选择的研究，旨在比较厄洛替尼与厄洛替尼联合化疗在一线治疗晚期非小细胞肺癌中的疗效。
J Clin Oncol. 2011 Sep 10;29(26):3567-73. doi: 10.1200/JCO.2010.34.4929. Epub 2011 Aug 8.
4
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.厄洛替尼对比化疗用于治疗晚期 EGFR 突变阳性非小细胞肺癌患者的一线治疗（OPTIMAL、CTONG-0802）：一项多中心、开放标签、随机、III 期研究。
Lancet Oncol. 2011 Aug;12(8):735-42. doi: 10.1016/S1470-2045(11)70184-X. Epub 2011 Jul 23.
5
Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy.一线化疗缓解情况对晚期非小细胞肺癌（NSCLC）患者厄洛替尼维持治疗生存获益的影响。
Ann Oncol. 2012 Feb;23(2):388-94. doi: 10.1093/annonc/mdr125. Epub 2011 May 24.
6
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.吉非替尼或化疗用于治疗具有突变型 EGFR 的非小细胞肺癌。
N Engl J Med. 2010 Jun 24;362(25):2380-8. doi: 10.1056/NEJMoa0909530.
7
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.厄洛替尼作为晚期非小细胞肺癌的维持治疗：一项多中心、随机、安慰剂对照的 3 期研究。
Lancet Oncol. 2010 Jun;11(6):521-9. doi: 10.1016/S1470-2045(10)70112-1. Epub 2010 May 20.
8
Phase II study of erlotinib for chemotherapy-naïve patients with advanced or metastatic non-small cell lung cancer who are ineligible for platinum doublets.厄洛替尼治疗不适合铂类双药化疗的晚期或转移性非小细胞肺癌化疗初治患者的 II 期研究。
Cancer Chemother Pharmacol. 2011 Jan;67(1):35-9. doi: 10.1007/s00280-010-1280-6. Epub 2010 Feb 25.
9
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.吉非替尼对比顺铂联合多西他赛用于治疗表皮生长因子受体突变的非小细胞肺癌患者（WJTOG3405）：一项开放标签、随机对照 3 期临床试验。
Lancet Oncol. 2010 Feb;11(2):121-8. doi: 10.1016/S1470-2045(09)70364-X. Epub 2009 Dec 18.
10
Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer.厄洛替尼序贯化疗作为晚期非小细胞肺癌一线治疗的随机、安慰剂对照II期研究
J Clin Oncol. 2009 Oct 20;27(30):5080-7. doi: 10.1200/JCO.2008.21.5541. Epub 2009 Sep 8.
Zotero 插件